Latest Intelligence on Biotechnology in Netherlands

Published within

« | 1 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Licensing Week - August 16, 2002

Last week's licensing news had a truly global feel, with companies from the US, the UK, mainland Europe and Japan getting in on the action. The week saw deals between; AstraZeneca and Xenogen; Crucell and GenVec; Takeda and Human Genome Sciences; Adolor and Eli Lilly; and Anadys and Roche.

Published By Datamonitor
15 Aug 2002
CommentWire
CommentWire

Crucell: failed vaccine disappoints

Crucell has halted development of Aerugen, its late-stage vaccine candidate for the prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients, following disappointing phase III trial results. Although this is something of a setback for vaccine development within the field of cystic fibrosis, other efforts focusing on ion channel therapy still provide a glimmer of hope.

Published By Datamonitor
19 Jul 2006

« | 1 | » »|

No help is available.